Ibrahim Maattallaoui

Mr. Ibrahim Maattallaoui

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Molecules
Verified
Journal Article
Open access
PDF file
Ibrahim MaattallaouiIbrahim Maattallaoui
Ibrahim Maattallaoui
MSMahamadou Sakho
Mahamadou Sakho
AMABDELLAH MAATALLAOUI
ABDELLAH MAATALLAOUI
Enrique Barrajon-CatalanEnrique Barrajon-Catalan
Enrique Barrajon-Catalan
Noureddine EL AOUADNoureddine EL AOUAD
Noureddine EL AOUAD
Human dihydrofolate reductase (hDHFR) is a crucial cellular enzyme in folate metabolic pathway, where it catalyzes the reduction of dihydrofolate into tetrahydrofolate (THF) and an important cofactor involved in DNA, RNA, protein biosynthesis and cell proliferation. Due to its importance, hDHFR has become a promising target for therapeutic development, particularly in treating cancer, bacterial infections, and autoimmune diseases. Its inhibition has found clinical value in antitumor, antimicrobial and antiprotozoal treatment; however, the emergence of resistance to existing hDHFR inhibitors necessitates the development of new and more potent compounds. In the current study, we propose a cheminformatics-based approach using machine learning to develop predictive models of hDHFR bioactivity. We used three types of molecular descriptors in the form of fingerprints, i.e., PubChem, Substructure, and MACCS, to capture structural properties associated with hDHFR inhibition. Predictive models were built using a random forest algorithm optimized through hyperparameter tuning. Feature selection was performed using Recursive Feature Elimination (RFE), and dataset dimensionality was reduced by removing outliers through Principal Component Analysis (PCA) to optimize model performance and reducing overfitting and weak predictivity. The resulting models are validated through external test sets, domain applicability analysis, and interpretation of influential molecular features via random forest feature importance selection plots and correlation matrix analysis. All three models exhibited strong predictive capabilities, with R-squared (R2) values ranging from 0.9849 to 0.9934 for the training set and 0.9381 to 0.9591 for the test set. These final predictive models were further incorporated into an accessible web application, enabling users to estimate the bioactivity of new compounds targeting hDHFR.

16 October 2026 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
Ibrahim MaattallaouiIbrahim Maattallaoui
Ibrahim Maattallaoui
Noureddine EL AOUADNoureddine EL AOUAD
Noureddine EL AOUAD
Human dihydrofolate reductase (hDHFR) is a key enzyme in folate metabolism and an established therapeutic target in cancer and other diseases. Methotrexate (MTX), a clinically used hDHFR inhibitor, is effective but associated with toxicity and resistance, highlighting the need for alternative inhibitors. Here, we developed and validated a structure-based pharmacophore model derived from the hDHFR–MTX crystal complex and applied it to DrugBank for drug repurposing. Pharmacophore screening, Lipinski filtering, molecular docking, GNINA CNN scoring, and protein–ligand interaction analysis were integrated to prioritize potential hDHFR-targeting drugs. Ertugliflozin emerged as a promising computational candidate, warranting further molecular dynamics and experimental validation.